Triglycerides and HDL Cholesterol
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 56 of the 59 references it cites were found in a registry or an index.
Abstract
Diabetes carries a high risk of atherosclerosis, and cardiovascular disease, especially coronary heart disease (CHD) and stroke, is by far the leading cause of death among patients with type 2 diabetes. Although statins reduce the risk of major vascular events by about one-fifth per millimole per liter reduction in LDL cholesterol, with similar proportional reductions in major coronary events, stroke, and the need for coronary revascularization, the residual risk remains high. In the Scandinavian Simvastatin Survival Study (4S) (1), although the relative risk reduction in diabetic patients was larger than in nondiabetic patients, simvastatin-treated diabetic patients were still at higher risk of death than the placebo-treated nondiabetic patients. Multifactorial intervention reduces the risk even further, but significant danger remains. Current guidelines call for an aggressive treatment strategy to reduce LDL cholesterol, blood pressure, and glucose levels in diabetic patients, but data concerning the management of high triglyceride (TG) levels and low HDL cholesterol levels remains inconclusive. This article reviews the data concerning diabetic dyslipidemia and its management. DIABETIC DYSLIPIDEMIA — The cluster of lipid abnormalities associated with type 2 diabetes is defined by a high concentration of TG and small dense LDL and a low concentration of HDL cholesterol. Plasma LDL cholesterol levels are generally normal. Insulin resistance is believed to contribute to this atherogenic dyslipidemia by increasing the hepatic secretion of VLDL and other apolipoprotein (apo)B-containing lipoprotein particles,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death”
In the citing paper
“many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53,54,55]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“FUTURE PROSPECTS — The concept of cholesterol ester transfer protein (CETP) inhibition suffered a serious blow when the results of the ILLUMINATE trial demonstrated an increase in adverse events in patients treated with torcetrapib (42).”
BackgroundYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979 · cited 2×
“The simvastatin-niacin combination was also associated with a 90% reduction in the composite end point of major cardiovascular events (32).”
BackgroundFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 1×
“In the Coronary Drug Project, niacin reduced mortality among myocardial infarction survivors, although, contrary to the relatively rapid effect of statins, mortality rates were almost identical throughout the first 68 months of follow-up and did not begin to diverge until month 72 (31).”
ResultNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · cited 1×
“In one small study, intravenous recombinant apoA-I Milano/phospholipid complexes produced regression of coronary atherosclerosis as measured by intravascular ultrasound (44).”
BackgroundHokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706 · cited 1×
“In a meta-analysis of 17 population-based prospective studies, increased plasma TG levels were associated with increased coronary disease risk in both men and women, after adjustment for HDL cholesterol and other risk factors (7).”
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619 · cited 3×
“and markers of insulin resistance (9).”
InfluentialHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329 · cited 1×
“In the Helsinki Heart Study, treatment with gemfibrozil resulted in a 71% lower incidence of CHD events in the subgroup of patients free of CHD at baseline, with the LDL cholesterol/HDL cholesterol ratio above 5 and TG level 200 mg/dl (27).”
MethodMarchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896 · cited 1×
“A similar cholesterol ester protein-mediated transfer of TGs from VLDL to LDL contributes to the formation of small dense LDL particles (6).”
BackgroundTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890 · cited 2×
“In addition to the beneficial effects on intima-media thickness progression, a large, although statistically nonsignificant, reduction in recurrent CHD events was also noted (33).”
BackgroundStatins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724 · cited 1×
“In a post hoc analysis of four prospective randomized intravascular ultrasound trials, a decrease in LDL cholesterol levels and an increase in HDL cholesterol levels were independent predictors of atheroma regression (20).”
MethodHooper, L., Thompson, R. L., Harrison, R. A., Summerbell, C. D., Ness, A. R., Moore, H. J., Worthington, H. V., Durrington, P. N., Higgins, J. P. T., Capps, N. E., et al. (2006) · BMJ · doi:10.1136/bmj.38755.366331.2f · Cited by 676 · cited 1×
“Three large trials—Gruppo Italiano per lo Studio della Sopravvivenza nell’Infartio miocardico (GISSI)-Prevenzione (GISSI-Prevenzione) (37), Japan EPA Lipid Intervention Study (JELIS) (38), and GISSI-heart failure (39)—have shown clinical outcome benefits of dietary supplementation with -3 fatty acids, but a recent sys…”
BackgroundMiller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.038 · Cited by 610
Marx, N., Sukhova, G. K., Collins, T., Libby, P., & Plutzky, J. (1999) · Circulation · doi:10.1161/01.cir.99.24.3125 · Cited by 599
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Goldbourt, U., Yaari, S., & Medalie, J. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.1.107 · Cited by 391
Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69292-1 · Cited by 387
van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S. G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.060 · Cited by 374 · cited 1×
“Recent studies, however, demonstrated that it may be the level of apoA-I, rather than the level of HDL cholesterol, that is important in reducing the risk of atherosclerosis (16).”
BackgroundMarx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Koenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 331
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319 · cited 1×
“This may also be the result of a diminished suppressive effect of insulin on apoB secretion, either at the level of the regulation of apoB degradation, or inhibition of microsomal TG transfer protein activity (4).”
BackgroundTenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 311 · cited 1×
“In the Bezafibrate Infarction Prevention (BIP) study, although bezafibrate had no effect on all-cause and cardiac mortality in the entire study population, it was associated with a 31% relative reduction in the risk of myocardial infarction in patients with the metabolic syndrome (28).”
BackgroundVakkilainen, J., Steiner, G., Ansquer, J.-C., Aubin, F., Rattier, S., Foucher, C., Hamsten, A., & Taskinen, M.-R. (2003) · Circulation · doi:10.1161/01.cir.0000057982.50167.6e · Cited by 270 · cited 1×
“This effect seemed to be mediated, at least in part, by changes in LDL particle size (25).”
BackgroundApolipoprotein A-I Mimetic Peptides
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S., Hough, G., Grijalva, V. R., Yu, N., Ansell, B. J., Datta, G., Garber, D. W., et al. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000165694.39518.95 · Cited by 246 · cited 1×
“ApoA-I mimetic peptides are being investigated and, at least in animal models, were found to increase the formation of pre- HDL, improve HDL-mediated cholesterol efflux, increase paraoxonase activity, and convert HDL from proinflammatory to antiinflammatory (45).”
BackgroundDurrington, P. N. (2001) · Heart · doi:10.1136/heart.85.5.544 · Cited by 243 · cited 1×
“In one study, the addition of -3 fatty acids to simvastatin significantly decreased TG, VLDL, and nonHDL cholesterol levels compared with simvastatin alone (34).”
BackgroundPrevalence of risk factors in men with premature coronary artery disease
Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90924-a · Cited by 243
Bloomfield, D., Carlson, G. L., Sapre, A., Tribble, D., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 243
Prevalence of Risk Factors in Men With Premature Coronary Artery Disease
Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J. (1992) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-199203010-00011 · Cited by 217
The ORIGIN Trial Investigators (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.09.009 · Cited by 204
Alterations of lipid metabolism in healthy volunteers during long‐term ethanol intake
BELFRAGE, P., BERG, B., HÄGERSTRAND, I., NILSSON‐EHLE, P., TORNQVIST, H., & WIEBE, T. (1977) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1977.tb01584.x · Cited by 180
Chan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., Redgrave, T. G., & Mori, T. A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2377 · Cited by 160 · cited 1×
“In obese insulinresistant men with dyslipidemia, consistent with the metabolic syndrome, the combination of -3 fatty acids and atorvastatin decreased VLDL-apoB secretion and increased the fractional catabolic rate of VLDL-apoB and conversion of VLDL to LDL (35).”
BackgroundMuhlestein, J. B., May, H. T., Jensen, J. R., Horne, B. D., Lanman, R. B., Lavasani, F., Wolfert, R. L., Pearson, R. R., Yannicelli, H. D., & Anderson, J. L. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.009 · Cited by 147 · cited 2×
“The lipid-lowering arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, involving about 5,500 patients with type 2 diabetes, is comparing the effect of simvastatin plus fenofibrate to simvastatin alone on cardiovascular morbidity and mortality (30).”
BackgroundDyslipidemia in type 2 diabetes
Krauss, R. M., & Siri, P. W. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.004 · Cited by 137 · cited 1×
“Insulin resistance is believed to contribute to this atherogenic dyslipidemia by increasing the hepatic secretion of VLDL and other apolipoprotein (apo)B-containing lipoprotein particles, as a result of increased free fatty acid flux to the liver (2,3).”
BackgroundLaws, A., Hoen, H. M., Selby, J. V., Saad, M. F., Haffner, S. M., & Howard, B. V. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.1.64 · Cited by 128
Hausmann, D., Johnson, J. A., Sudhir, K., Mullen, W. L., Friedrich, G., Fitzgerald, P., Chou, T. M., Ports, T., Kane, J., Malloy, M., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00048-4 · Cited by 117
Johnsen, S. H., Mathiesen, E. B., Fosse, E., Joakimsen, O., Stensland-Bugge, E., Njølstad, I., & Arnesen, E. (2005) · Circulation · doi:10.1161/circulationaha.104.522706 · Cited by 115
Hopkins, G. J., & Barter, P. J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38740-x · Cited by 103
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.1.37 · Cited by 99 · cited 1×
“In another study, the combination of atorvastatin -3 fatty acids increased HDL2 levels, thereby correcting the functional defect in HDL characteristic of the metabolic syndrome (36).”
BackgroundHYPER‐α‐LIPOPROTEINEMIA IN MEN EXPOSED TO CHLORINATED HYDROCARBON PESTICIDES
Carlson, L. A., & Kolmodin‐Hedman, B. (1972) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1972.tb04773.x · Cited by 78
Hogue, J., Lamarche, B., Tremblay, A. J., Bergeron, J., Gagné, C., & Couture, P. (2008) · Metabolism · doi:10.1016/j.metabol.2007.10.014 · Cited by 63 · cited 1×
“However, data on the effect of fibrates on markers of inflammation, cell adhesion, and oxidation are controversial: in one study, fenofibrate did not reduce plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1 (sICAM)-1, vascular cell adhesion molecule-1 (sVCAM-1), matrix metalloproteinase-9…”
BackgroundElevation of High‐Density Lipoprotein in Epileptic Patients Treated with Phenytoin
Nikkilä, E. A., Kaste, M., Ehnholm, C., & Viikari, J. S. A. (1978) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1978.tb08483.x · Cited by 44
Effects of chlorinated hydrocarbons on plasma α-lipoprotein cholesterol in rats
Ishikawa, T. T., McNeely, S., Steiner, P. M., Glueck, C. J., Mellies, M. J., Gartside, P. S., & McMillin, C. R. (1978) · Metabolism · doi:10.1016/0026-0495(78)90127-0 · Cited by 39
Chronic Alcohol Abuse and High Density Lipoprotein Cholesterol
Barboriak, J. J., Jacobson, G. R., Cushman, P., Herrington, R. E., Lipo, R. F., Daley, M. E., & Anderson, A. J. (1980) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1980.tb04829.x · Cited by 37
Durrington, P. N. (1979) · Clinical Science · doi:10.1042/cs0560501 · Cited by 35
Increased Carotid Artery Intima-Media Thickness in Subjects With Primary Hypoalphalipoproteinemia
Baldassarre, D., Amato, M., Pustina, L., Tremoli, E., Sirtori, C. R., Calabresi, L., & Franceschini, G. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0202.104848 · Cited by 29 · cited 1×
“milial hypercholesterolemia (14), while a”
The Liver X Receptor and Atherosclerosis
Scott, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmcibr075951 · Cited by 26 · cited 1×
“Finally, liver X receptor agonists are also investigated as a possible measure of increasing reverse cholesterol transport and reversing atherosclerosis (47).”
BackgroundDIETARY FATS AND CORONARY HEART DISEASE
Sinclair, H. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90957-5 · Cited by 22
Enzyme Induction and Serum and Lipoprotein Lipids: A Study of Glutethimide in Normal Subjects
Bolton, C., Jackson, L., Roberts, C. J., & Hartog, M. (1980) · Clinical Science · doi:10.1042/cs0580419 · Cited by 11
Anderson, T. J., Charbonneau, F., Chan, S., & Lonn, E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.12.030 · Cited by 8 · cited 1×
“Large unilamellar vesicles have been developed to serve as “sink or sponge” binding cholesterol from HDL, thus regenerating HDL particles able to take up cholesterol from peripheral tissues (46).”
Background
Cited by
Ozder, A. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-183 · Cited by 187
Choi, Y. J., Jeon, S.-M., & Shin, S. (2020) · Nutrients · doi:10.3390/nu12072005 · Cited by 193
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death, and many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53–55].”
Obesity and its impact on female reproductive health: unraveling the connections
Zheng, L., Yang, L., Guo, Z., Yao, N., Zhang, S., & Pu, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1326546 · Cited by 209
“Elevated triglycerides, reduced high-density lipoprotein-cholesterol (HDL-C) levels, and a general dyslipidemic state have implications not only for cardiovascular health but also for reproductive outcomes (50).”
BackgroundChen, Y. Q., Pottanat, T. G., Siegel, R. W., Ehsani, M., Qian, Y.-W., Zhen, E. Y., Regmi, A., Roell, W. C., Guo, H., Luo, M. J., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000781 · Cited by 147
Chaudhary, R., Likidlilid, A., Peerapatdit, T., Tresukosol, D., Srisuma, S., Ratanamaneechat, S., & Sriratanasathavorn, C. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-36 · Cited by 135
Metadata
- Authors
- Bitzur, R., Cohen, H., Kamari, Y., Shaish, A., & Harats, D.
- Affiliations
- Sheba Medical Center (IL)
- Corresponding author
- Bitzur, Rafael
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S373-S377
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2811435
- OpenAlex
- W2170606689
- Cited by
- 132
- References
- 59
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 10 · 2021: 16 · 2020: 14 · 2019: 6 · 2018: 10 · 2017: 9 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 8 · 2012: 5
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- triglycerides, HDL cholesterol, type 2 diabetes, diabetic dyslipidemia, residual cardiovascular risk, statins, small dense LDL, insulin resistance, atherogenic dyslipidemia, cardiovascular disease, lipid control
- MeSH terms
- Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Cholesterol, HDL, Niacin, Triglycerides, Fatty Acids, Omega-3, Stroke, PPAR alpha, Diabetes Complications, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.